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Introduction {#sec005}
============

Obesity is an international issue related to many serious diseases like diabetes and cardiovascular diseases that impose a huge burden on both individual and public health \[[@pone.0231308.ref001]--[@pone.0231308.ref003]\]. Based on international reference standards, the body mass index (BMI) is the most common measurement for the determination of obesity both in clinical practice and research \[[@pone.0231308.ref004],[@pone.0231308.ref005]\]. However, more and more studies confirmed that central obesity, also known as visceral obesity, offers more predictive power for type 2 diabetes, cardiovascular risk and metabolic dysfunctions than whole-body adiposity \[[@pone.0231308.ref006]--[@pone.0231308.ref008]\]. Thus, for the failure to evaluate body fat distribution, BMI is replaced by some other anthropometric parameters to predict central obesity and insulin resistance, such as waist circumference (WC) and waist to hip ratio (WHR) \[[@pone.0231308.ref009]--[@pone.0231308.ref012]\].

Among various methods, WC is used as the most common anthropometric index of abdominal visceral fat accumulation and insulin resistance (IR), which were the indicators of cardiovascular risks in both men and women \[[@pone.0231308.ref003],[@pone.0231308.ref013]\]. However, there remain a number of limitations of WC, such as the absence of a standard approach of measurement; the volatility of measuring results from the influence of dining and diverse health conditions \[[@pone.0231308.ref010]\]. In addition, while it is well documented that adipose tissue, especially volume of visceral adipose tissue was strongly correlated with cardiovascular diseases, insulin resistance and diabetes mellitus \[[@pone.0231308.ref014]\], WC alone to predict central obesity seems to be not enough since its failure to distinguish whether it is caused by volume of visceral or abdominal subcutaneous adipose tissue. Therefore, some researches were conducted to explore novel indexes to be more accurate and practical \[[@pone.0231308.ref010],[@pone.0231308.ref015]--[@pone.0231308.ref017]\]. Recently, arm-fat percentage or mid-upper arm circumference (MUAC) were suggested as novel predictors of central obesity and IR in population with normal weight, overweight or obesity \[[@pone.0231308.ref018]--[@pone.0231308.ref020]\]. However, there is little data to evaluate the role of MUAC in detecting IR and central obesity in diabetic patients. A large amount of studies had proved that the IR and central obesity in patients with diabetes were quite different from other populations \[[@pone.0231308.ref021],[@pone.0231308.ref022]\]. Type 2 diabetes is mainly characterized by insulin resistance. Most recently, in Groop L's and Ji L's suggestions of novel diabetes classification, diabetes was stratified into five types (in Groop L's study) or four types (in Ji L's study) \[[@pone.0231308.ref023],[@pone.0231308.ref024]\]. In their studies, diabetes complications substantially increased in patients with severe insulin-resistant diabetes, which reinforced the importance of IR and central obesity in diabetic patients. As a result, the association of MUAC and IR and central obesity in diabetes might be quite different from other populations as well. Therefore, precisely identifying the central obesity and IR in closely related to type 2 diabetes is of great importance. As the evaluation of MUAC can be easily obtained in clinical practice, our study aimed to evaluate whether the MUAC can be served as an indicator of central obesity and IR in type 2 diabetes. Besides, we further investigate whether MUAC is superior to other anthropometric parameters in measuring central obesity and IR in subjects with type 2 diabetes.

Materials and methods {#sec006}
=====================

Study population {#sec007}
----------------

From April 2015 to May 2017, 103 subjects were recruited in our study. The patients were selected from inpatient clinics who met the following criteria: aged above 18 years, diagnosed with type 2 diabetes (according to the WHO diabetes criteria) \[[@pone.0231308.ref025]\], without insulin treatment, Sulphonylurea, sodium-dependent glucose transporters-2 inhibitors (SGLT-2i) or glucagon-like peptide-1 (GLP-1) analog for at least 2 weeks (hypoglycemic agents in [S1 Table](#pone.0231308.s001){ref-type="supplementary-material"}), not having severe disease and be free of any acute infection during 2 weeks before the inclusion. The medications of hypertension, hyperlipidemia and hyperuricemia were displayed in the [S2](#pone.0231308.s002){ref-type="supplementary-material"}--[S4](#pone.0231308.s004){ref-type="supplementary-material"} Tables, respectively. The protocol was approved by the ethics committee of the Third Affiliated Hospital of Sun Yat-sen University. All subjects provided written informed consent before screening.

Anthropometric measures {#sec008}
-----------------------

Body height and weight were measured by the researchers and BMI was calculated as body weight(kg) divided by the square of the height(m). Hip circumference (HC) was the horizontal length between the most prominent parts of the buttocks, waist circumference (WC) was measured at the mid-position between the iliac crest and the last rib \[[@pone.0231308.ref026]\], and the waist-to-hip ratio (WHR) was calculated. Mid-upper arm circumference (MUAC) was measured at the mid-arm between the shoulder and elbow \[[@pone.0231308.ref018]\].

Blood biochemical assays {#sec009}
------------------------

Venous blood samples were collected from participants to determine metabolic markers, including fasting blood-glucose, total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), triglyceride (TG), and uric acid (UA), using an automated enzymatic method (Hitachi, Japan, 7600--020 autonomic analyzer). High-pressure liquid chromatography (BIO-RAD, USA, D-10 analyzer) was used to measure the HbA1c level. Plasma insulin was evaluated by competitive radioimmunoassay (Centaur XP immunoassay system, Siemens Healthcare Diagnostics, New York, NY). The Homeostasis Model Assessment-Insulin Resistance (HOMA-IR) index, calculated by the formula: fasting plasma insulin (mU/L) x fasting plasma glucose (mmol/L)/22.5 \[[@pone.0231308.ref027]\], was used to assess Insulin Resistance (IR).

For man, waist circumference ≥ 85cm was used to define central obesity and for women as waist circumference ≥ 80cm \[[@pone.0231308.ref028]\].

Statistical analysis {#sec010}
--------------------

The SPSS program for Windows (version 22.0) was utilized to process the analysis. Continuous variables of clinical characteristics were presented as mean±S.D. Differences between groups were evaluated by t-test, chi-square test or Wilcoxon rank-sum test. Data of non-normal distributions were logarithmically transformed before statistical analysis. Pearson or Spearman correlations were conducted to analyze the associations between two variables. Variables that were significantly related to the objective variable were tested for independence using multivariate linear regression analysis. The risk factors of central obesity were evaluated by logistic regression. The accuracy of anthropometric parameters to predict central obesity was evaluated by using receiver operator characteristic (ROC) curve analysis. The specificity and sensitivity of MUAC were calculated for each cut-off point in the sample. P value below 0.05 was examined statistically significant.

Results {#sec011}
=======

Baseline characteristics {#sec012}
------------------------

The study sample consisted of 103 individuals (mean age: 51.4±13.6 years) with 60 male (58%). The clinical characteristics of the subjects are shown in [Table 1](#pone.0231308.t001){ref-type="table"}. The values of BMI (male, 26.27±4.58kg/m2, female, 24.00±2.73kg/m2), WC (male, 93.78±10.67cm, female, 88.35±6.88cm) and MUAC (male, 32.82±3.38cm, female, 30.11±2.62cm) were significantly higher while TC (male, 4.77±1.28mmol/L, female, 5.47±1.91mmol/L) and HDL-C (male, 0.96±0.23mmol/L, female, 1.21±0.33mmol/L) were significantly lower in male than those in female.

10.1371/journal.pone.0231308.t001

###### General characteristics of study subjects.

![](pone.0231308.t001){#pone.0231308.t001g}

  Parameters                  All(N = 103)   Men(N = 60)     Women(N = 43)   P(men vs women)
  --------------------------- -------------- --------------- --------------- -----------------
  Age (years)                 51.4±13.6      48.9±14.2       54.9±12.2       0.03
  Diabetes duration (years)   8.79±3.13      9.82±3.21       8.13±2.11       0.78
  BP (mmHg)                   135/83         145/92          134/80          0.23
  FBG (mmol/L)                8.70±3.34      8.62±2.79       8.83±4.02       0.75
  BMI (kg/m^2^)               25.32±4.05     26.27±4.58      24.00±2.73      0.005
  WC (cm)                     91.51±9.62     93.78±10.67     88.35±6.88      0.004
  WHR                         0.94±0.06      0.95±0.05       0.93±0.06       0.13
  MUAC (cm)                   31.68±3.35     32.82±3.38      30.11±2.62      \<0.001
  TG (mmol/L)                 2.15±2.55      2.23±2.13       2.04±3.06       0.71
  TC (mmol/L)                 5.07±1.61      4.77±1.28       5.47±1.91       0.03
  HDL-C (mmol/L)              1.06±0.30      0.96±0.23       1.21±0.33       \<0.001
  LDL-C (mmol/L)              3.17±1.06      3.18±0.99       3.17±1.15       0.95
  UA (μmol/L)                 354.17±99.49   368.20±100.16   334.60±96.29    0.09
  HbA1C (%)                   9.04±2.51      9.16±2.30       8.86±2.79       0.56
  LogHOMA-IR                  0.61±0.23      0.64±0.23       0.57±0.22       0.13

BMI, Body Mass Index; MUAC, Mid-upper Arm Circumference; WC, Waist Circumstance; WHR, Waist-to-hip Ratio; UA, Uric Acid; TG, Triglyceride; TC, Total Cholesterol; HDL-C, High-Density Lipoprotein Cholesterol; LDL-C, Low-Density Lipoprotein Cholesterol; HbA1C, Hemoglobin A1c; HOMA-IR, Homeostatic Model Assessment of Insulin Resistance.

In addition, the subjects were categorized based on tertiles cut-points of arm circumference level (tertile 1, MUAC \< 29.50cm; tertile 2, 29.50cm≤MUAC≤32.60cm; tertile 3, MUAC \> 32.60cm). As shown in [Table 2](#pone.0231308.t002){ref-type="table"}, the value of BMI, WC and LogHOMA-IR of patients were significantly higher in the groups with higher MUAC. Moreover, the percentages of central obesity, identified by the measurement of waist circumference, were 55.8%, 85.7% and 97.1% respectively in the three groups (*P*\<0.01).

10.1371/journal.pone.0231308.t002

###### Characteristics of subjects according to mid-upper arm circumference tertiles.

![](pone.0231308.t002){#pone.0231308.t002g}

                   Tertile 1 (n = 34)   Tertile 2 (n = 35)   Tertile 3 (n = 34)   P value            
  ---------------- -------------------- -------------------- -------------------- --------- -------- --------
  Age(years)       55.2±11.7            52.1±12.5            46.9±12.5            0.33      0.01     0.11
  BMI(kg/m^2^)     21.97±1.07           24.51±1.27           29.52±4.21           \<0.01    \<0.01   \<0.01
  MUAC (cm)        28.36±0.90           31.26±0.87           35.47±2.62           \-        \-       \-
  WC (cm)          84.59±7.07           89.94±5.32           100.04±8.93          \<0.01    \<0.01   \<0.01
  WHR              0.92±0.07            0.95±0.04            0.97±0.06            0.09      \<0.01   0.13
  HbA1C (%)        9.29±3.01            8.98±2.26            8.84±2.15            0.62      0.60     0.83
  FBG (mmol/L)     9.40±4.38            8.26±270             8.45±2.64            0.16      0.24     0.83
  BP (mmHg)        135/94               142/98               138/92               0.24      0.35     0.48
  TC (mmol/l)      4.96±1.32            5.02±1.65            5.22±1.85            0.90      0.61     0.53
  TG (mmol/l)      1.36±0.71            2.17±2.01            2.93±3.76            0.18      0.01     0.21
  HDL-C (mmol/l)   1.24±0.34            1.01±0.21            0.95±0.26            \<0.01    \<0.01   0.34
  LDL-C (mmol/l)   2.85±0.85            2.93±1.21            3.74±0.85            0.36      \<0.01   0.02
  UA(umol/L)       312.06±74.04         358.51±106.79        391.82±100.27        0.05      \<0.01   0.15
  LogHOMA-IR       0.46±0.21            0.63±0.17            0.74±0.21            \<0.01    \<0.01   0.02

For list of abbreviations, see [Table 1](#pone.0231308.t001){ref-type="table"}.

P value \<0.05 were considered significant.

Correlation of mid-upper arm circumference with central obesity parameters, metabolic variables and insulin resistance {#sec013}
----------------------------------------------------------------------------------------------------------------------

Correlation between the MUAC, central obesity markers and metabolic markers among all subjects were analyzed in our study. The MUAC positively correlated with BMI (r = 0.88, *P* \< 0.001) and the central obesity markers, WC (r = 0.74, *P* \< 0.001) and WHR (r = 0.30, *P* = 0.002). Among the traditional metabolic risk factors, MUAC showed a positive correlation with UA(r = 0.32, *P*\<0.001) and LDL-C (r = 0.40, *P*\<0.001) and negatively correlated with HDL-C (r = -0.32, *P* = 0.001) in all patients ([Fig 1](#pone.0231308.g001){ref-type="fig"}). Furthermore, the relationships shown in [Table 3](#pone.0231308.t003){ref-type="table"} were observed differently by gender. In both genders, MUAC correlated positively with BMI, WC and LDL-C, while the positive correlation with WHR, TG, UA and negative correlation with HDL-C were only shown in men. The association between MUAC and glycemic parameters was not found in our research.

![Relationship between MUAC (cm) and other anthropometric measurements in all subjects.\
Correlation assessed by Pearson analysis. MUAC, Mid-upper Arm Circumference; WC, Waist Circumstance; WHR, Waist-to-hip Ratio; BMI, Body Mass Index; UA, Uric Acid; LDL-C, Low-Density Lipoprotein Cholesterol; HDL-C, High-Density Lipoprotein Cholesterol.](pone.0231308.g001){#pone.0231308.g001}

10.1371/journal.pone.0231308.t003

###### Relationship between MUAC and other measurements by gender.

![](pone.0231308.t003){#pone.0231308.t003g}

  Variables        MUAC (cm)                     
  ---------------- ----------- --------- ------- ---------
  BMI (kg/m^2^)    0.95        \< 0.01   0.92    \< 0.01
  WC (cm)          0.82        \< 0.01   0.48    \< 0.01
  WHR              0.48        \< 0.01   0.10    0.50
  TG (mmol/L)      0.30        0.02      0.20    0.20
  TC (mmol/L)      0.19        0.13      0.07    0.65
  HDL-C (mmol/L)   -0.33       0.01      -0.23   0.14
  LDL-C (mmol/L)   0.57        \< 0.01   0.31    0.04
  UA (μmol/L)      0.39        \< 0.01   0.21    0.17
  HbA1C (%)        -0.18       0.17      0.07    0.65
  FBG (mmol/L)     -0.06       0.67      0.03    0.83
  LogHOMA-IR       0.52        \< 0.01   0.55    \< 0.01

For list of abbreviations, see [Table 1](#pone.0231308.t001){ref-type="table"}.

P values\<0.05 were considered significant.

Our results showed that MUAC (male, r = 0.52, *P*\<0.01, female, r = 0.55, *P*\<0.01), WC(male, r = 0.44, *P*\<0.01, female, r = 0.35, *P* = 0.02) and BMI (male, r = 0.46, *P*\<0.01, female, r = 0.51, *P*\<0.01) were positively related to LogHOMA-IR in both genders. However, we found that WHR (male, r = 0.33, *P* = 0.01, female, r = 0.74, *P* = 0.64) significantly positively correlated with LogHOMA-IR only in male. Additionally, MUAC was more strongly correlated with LogHOMA-IR than WC, BMI and WHR in both genders ([Table 4](#pone.0231308.t004){ref-type="table"}).

10.1371/journal.pone.0231308.t004

###### Relationship between HOMA-IR and other anthropometric measurements by gender.

![](pone.0231308.t004){#pone.0231308.t004g}

  Variable        LogHOMA-IR                    
  --------------- ------------ --------- ------ ---------
  MUAC (cm)       0.52         \< 0.01   0.55   \< 0.01
  WC (cm)         0.44         \< 0.01   0.35   0.02
  WHR             0.33         0.01      0.74   0.64
  BMI (kg/m^2^)   0.46         \< 0.01   0.51   \< 0.01

For list of abbreviations, see [Table 1](#pone.0231308.t001){ref-type="table"}.

P values\<0.05 were considered significant.

Linear regression analysis was conducted to identify the predictive effect of MUAC on the insulin resistance. After adjusting for confounding clinical parameters, including age, gender, WHR, UA, TG, LDL-C and HDL-C, the value of MUAC remained independently associated with LogHOMA-IR (β = 0.036, *P*\<0.001) ([Table 5](#pone.0231308.t005){ref-type="table"}).

10.1371/journal.pone.0231308.t005

###### Linear regression analysis of logHOMA-IR with different clinical characteristics.

![](pone.0231308.t005){#pone.0231308.t005g}

                                 β         P             95% CI        R^2^
  ----------- ------------------ --------- ------------- ------------- -------
  MUAC (cm)   Unadjusted model   0.039     \<0.001       0.028,0.051   0.319
  Model 1     0.041              \<0.001   0.029,0.054   0.327         
  Model 2     0.041              \<0.001   0.027,0.054   0.328         
  Model 3     0.036              \<0.001   0.021,0.050   0.392         

Model 1: adjusted for age and gender.

Model 2: adjusted for age, gender and Waist-to-hip Ratio(WHR).

Model 3: adjusted for model 2 plus Uric Acid(UA), Triglyceride(TG), Low-Density Lipoprotein Cholesterol(LDL-C) and High-Density Lipoprotein Cholesterol(HDL-C).

P values\<0.05 were considered significant.

The results of logistic regression analysis presented in [Table 6](#pone.0231308.t006){ref-type="table"} showed that only MUAC (OR, 2.129; 95% CI, 1.311--3.457; *P* = 0.002) and LDL-C (OR, 3.023; 95% CI, 1.090--8.383; *P* = 0.033) were associated with increased odds of central obesity after adjusting for age, gender, TG, AC,UA and use of statin.

10.1371/journal.pone.0231308.t006

###### Logistic regression analysis of risk factors for central obesity.

![](pone.0231308.t006){#pone.0231308.t006g}

                   Confirmed Central Obesity                  
  ---------------- --------------------------- -------------- -------
  MUAC (cm)        2.129                       1.311, 3.457   0.002
  LDL-C (mmol/l)   3.023                       1.090, 8.383   0.033

Risk factors including Mid-upper Arm Circumference(MUAC), age, gender, Low-Density Lipoprotein Cholesterol(LDL-C), Triglyceride(TG), Uric Acid(UA) and Use of Statin.

P values\<0.05 were considered significant.

Optimal cut-off points of mid-upper arm circumference for central obesity {#sec014}
-------------------------------------------------------------------------

The proportion of central obesity was 81.7% in men and 83.7% in women. The ROC curves are presented in [Fig 2](#pone.0231308.g002){ref-type="fig"}, and the area under the curve (AUC) for MUAC as a predictor of central obesity was 0.922 for male and 0.788 for female. The best MUAC cutoff point for defining central obesity was 30.9cm for male (Youden index = 0.746, Sensitivity: 83.7%; Specificity: 90.9%) and 30.0cm for female (Youden index = 0.528, Sensitivity: 52.8%; Specificity: 99.9%).

![The receiver operating characteristic (ROC) curves for men and women to identify central obesity.\
**(a)** ROC curve for MUAC in men. AUC = 0.922 (*P* \< 0.001), 95% CI 0.852--0.992. Identified MUAC cutoff value = 30.9cm, Youden index = 0.746, Sensitivity: 83.7%; Specificity: 90.9%. **(b)** ROC curve for MUAC in women. AUC = 0.788 (*P* = 0.017), 95% CI 0.642--0.933. Identified MUAC cutoff value = 30.0cm, Youden index = 0.528, Sensitivity: 52.8%; Specificity: 99.9%. MUAC, Mid-upper Arm Circumference. AUC: areas under the curve.](pone.0231308.g002){#pone.0231308.g002}

Discussion {#sec015}
==========

Previous studies \[[@pone.0231308.ref006],[@pone.0231308.ref007],[@pone.0231308.ref029]--[@pone.0231308.ref031]\] in different subjects demonstrated that abdominal distribution of body fat was correlated with IR, type 2 diabetes, cardiovascular diseases and total mortality risk. And the hyperglycemia was more difficult to manage in individuals with both diabetes and central obesity compared with those with only diabetes \[[@pone.0231308.ref032]\]. As a result, to found out an appropriate and more easily conducted method to identity central obesity and subsequently choose appropriate hypoglycemic agents could lead to better control of hyperglycemia and eventually reduce the mortality in diabetes. In Rerksuppaphol S' study, MUAC was suggested to be a simple and accurate parameter to identify overweight and obesity in Thai school-age children \[[@pone.0231308.ref033]\]. In an observational, multinational cross-sectional study with 7337 children aged 9--11 years, MUAC was shown to be a suitable method to detect obesity in children \[[@pone.0231308.ref034]\]. Moreover, Mazıcıoğlu and his group has demonstrated that MUAC could be a useful measurement in screening body fat distribution in children \[[@pone.0231308.ref035]\]. However, the subjects of those studies were all not patients with diabetes. In our study, we focused on the MUAC especially in type 2 diabetic patients and found that MUAC could serve as a simple and practical tool to better screen and identify central obesity among type 2 diabetic patients. As shown in the results, both the value of WC and the percentage of patients with central obesity were larger in the group with higher MUAC than those in the group with lower MUAC, which indicated the association between MUAC and central obesity in diabetes. In addition, MUAC correlated well with other anthropometric measurements in central obesity patients with diabetes. In both genders, MUAC was significantly associated with WC and BMI, which indicates that MUAC could be used as an effective indicator for both central obesity and overall obesity. Furthermore, in our study, gender-specific cut-off points of the MUAC for central obesity were also established. Based on our analyses, MUAC≥30.9cm was determined as the best cutoff value for men to define population with central obesity, and≥30cm for women, with 92.2% accuracy for men and 78.8% accuracy for women. To our best knowledge, this was the first study to evaluate the association between MUAC and central obesity and to determine the cut-off value of the MUAC for the prediction of central obesity especially in patients with type 2 diabetes.

Another feature of our research was the positive correlation between the MUAC and IR among Chinese type 2 diabetic patients. In our research, we found that MUAC has a positive correlation with HOMA-IR levels, which has been demonstrated to be the indicator of insulin resistance. The relationship between MUAC and IR was also confirmed in recent studies \[[@pone.0231308.ref018],[@pone.0231308.ref020]\]. The study in Pakistan \[[@pone.0231308.ref018]\] focused on children with majority of normal BMI found that arm-fat percentage is positively correlated with insulin levels. In a study conducted among 147 adults with overweight or obesity, Gómez-García et al \[[@pone.0231308.ref020]\] made a conclusion that mid arm circumference was a better predictor of IR. The subjects in these studies, however, were all not patients with diabetes. Unlike previous studies, we further explored the relationship between MUAC and IR among type 2 diabetes. As diabetes, a metabolic disorder causing disease, has been proved to be a more important factor than obesity in causing IR \[[@pone.0231308.ref036]\], results in our study further demonstrated that the increase of MUAC could serve as another important indicator of causing IR among diabetic patients. Furthermore, we found MUAC might be superior to WC (Men: r~MUAC~ = 0.52, r~WC~ = 0.44; Women: r~MUAC~ = 0.55, r~WC~ = 0.35) in measuring IR in type 2 diabetes which indicated that MUAC could be used as a better screening method of IR in type 2 diabetes.

We also evaluated the association between MUAC and metabolic risk factors including plasma UA and lipid. We found that MUAC was correlated positively with UA, LDL-C and negatively with HDL-C, indicating a higher risk of developing metabolic disorders in a population with a larger MUAC, which reminded us of taking more concern on the metabolic risk factors in this population. It is interesting that while MUAC correlated with BMI, waist circumference and LDL-C in both genders, but the correlation between MUAC and WHR, Tg, Uric acid, and HDL cholesterol in women was not observed. The plausible reason for sex difference of WHR may be due to the different fat distribution during aging. Men have consistent fat distribution during aging, which is always characterized with more visceral fat in the abdomen (apple shape), but women have more subcutaneous fat in the hip and thighs (pear shape) before menopause and have more visceral fat in abdomen (apple shape) after menopause due to the dramatical decline of estrogen \[[@pone.0231308.ref037]\]. The female patients in our study, however, were mainly during the menopause period. As a result, no correlation was shown between MUAC and WHR in these estrogen-changing women. The differences of Tg, Uric acid, and HDL cholesterol also attributed to the decline of estrogen after menopause for the protective role of estrogen for metabolic diseases \[[@pone.0231308.ref038]\]. Therefore, using the MUAC as a clinical tool to detect some metabolic risk factors, such as WHR, Tg, Uric acid, and HDL cholesterol in women should be cautious.

In our study, we found the MUAC was a simple and effective measurement for the determination of central obesity, insulin resistance and multiple metabolic risk factors among type 2 diabetic patients in China. Moreover, we also confirmed the cut-off values of MUAC for central obesity evaluation. Recently, Hou Y, et al also conducted a similar study about MUAC in the Chinese population \[[@pone.0231308.ref039]\]. However, the study was different from ours. Firstly, the population in their study included both participates with diabetes or normal glucose tolerance (NGT). The analysis of association between MUAC and central obesity and IR was conducted in all the participants but not just especially in patients with diabetes. The only analysis especially involved with diabetes was the multivariable logistic regression analysis base on the subgroups of diabetes or not. As we mentioned above, the central obesity, IR and MUAC in diabetes were quite different from those in participates with NGT, then the conclusion and significance of Hou's could not be drawn to the population with diabetes. Secondly, the aim of the study was to investigate the associations between MUAC and cardiometabolic risk profiles but not mainly the MUAC and central obesity and IR.

Comparing MUAC with WC and WHR, MUAC has some advantages: without influence of the moment of measurement (no influence of dining); simpler for both physicians and subjects, especially in the public and crowded places; more convenient and more socially acceptable, particularly for obese population; additionally, more accurate of the result for the unified method of detection. As a result, MUAC may be a better index in large epidemiological survey about central obesity and insulin resistance in type 2 diabetes.

Our research has some limitations. Firstly, the sample size in our research was relatively small. However, this is just a pilot study evaluating the association between MUAC and central obesity and IR, especially in patients with type 2 diabetes. Therefore, with the suggestive findings from this study, prospectively designed studies with more participants would be conducted in the near future. Secondly, the index of HOMA-IR, which represents insulin resistance levels, remains relatively simple and no international reference values. However, as we know, HOMA-IR has already been proved to be closely correlated with the hyperinsulinemic euglycemic clamp \[[@pone.0231308.ref040]\], the gold standard to evaluate IR. Therefore, we think the evaluation of IR in our study might be relatively simple but practical. Thirdly, the anti-diabetic agents and anti-hypertensive agents could influence insulin resistance, which might consequently cause effects on our results. It would be most appropriate to include completely drug-naïve subjects into our study. However, this was a cross-sectional study but not a case-control clinical trial, we could not intervene in any way to stop the anti-diabetic agents or any other medications as clinical trials do. We can also see pharmacotherapy of patients with T2DM, hyperlipidemia or hypertention were not stopped in many similar studies involving the investigation of insulin resistance \[[@pone.0231308.ref041]--[@pone.0231308.ref044]\]. Moreover, the subjects included in our study were mostly in their middle age. Sixty-eight percent of middle-age and elderly population in our society had at least one chronic disease \[[@pone.0231308.ref045]\]. In addition, the prevalence of hypertension and hyperlipidemia in patients with type 2 diabetes is 51.9% and 30.5% respectively \[[@pone.0231308.ref046]--[@pone.0231308.ref047]\]. As a society with dramatically increased aging population, we can hardly include the subjects at the middle age without any other diseases or any other drugs. Drug-naïve subjects will be included into our future study to minimize the effects of agents on insulin resistance. Despite the limitations, our results offered evidence that MUAC might be a screening tool that could predict central obesity and IR, which might be superior to WC and WHR in Chinese patients with type 2 diabetes.

In conclusion, higher MUAC is correlated with central obesity, insulin resistance and multiple metabolic risk indicators in Chinese subjects with type 2 diabetes. It could be expectable that MUAC will be widely applied in both research and clinical practice in future for its simplicity and stability.
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Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

We would appreciate receiving your revised manuscript by Nov 28 2019 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.
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<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. Please include your ethics statement from your methods section in the online metadata.

Additional Editor Comments:

Dear authors. Thank you for your work submitted to the journal. Please reply point by point to the comments of the reviewers. Regards

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Partly

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: I Don\'t Know

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: No

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: This paper investigated the utility of measuring mid-upper arm circumference (MUAC) as a surrogate for measuring waist circumference or waist to hips ratio when assessing insulin resistance in patients with type 2 diabetes. It is concluded that MUAC is a simple tool to measure central obesity and insulin resistance. It is of interest that while MUAC correlated with BMI, waist circumference and and LDL-C in both genders, It failed to correlate with WHR, Tg, Uric acid, and HDL cholesterol in women. The implication of this failure in women was not discussed adequately. The possible reason (women are pear or apple shape while men are always apple shape) and possible consequence of using the MUAC as a clinical tool in women was not discussed.

On Page 19 Line 3 it is stated that \"Furthermore we found MUAC might be superior to WC in measuring IR in type 2 diabetes\...\" It would be helpful to the reader to quote here the data and statistical result that support this statement.

Minor Points

Page 4 Para 2 Line 3 \"\...it remains a number of limitations od WC..\" should be \"\....there remain a number of limitations of WC..\"

Page 4 Para 2 Line 11 \"Therefore some Researches were conducted\.....\" should be \"Therefore som research was conducted\...\"

Page 4 Para 2 Line 15 \"However it remains little data to\...\" should be \"However there is little data to\...\"

There are many other examples where a native English speaker might help.

Reviewer \#2: Dear authors,

This article is interesting because authors investigated the importance MUAC. However I think this article has unavoidable problems to be confirmed.

\<1\> Considering this study was performed for T2DM patients, authors should investigate the effect of T2DM itself to results in detail. Authors wrote "without insulin treatment or other medications that could alter insulin secretion (such as Sulphonylurea) for at least 2 weeks, not having severe disease and be free of any acute infection during 2 weeks before the inclusion" at MATERIALS and METHODS and patients' HbA1c levels in Table 1. At first, authors should write details of agents for T2DM which patients were administered when they were investigated. For instance, almost all agents for T2DM affected to insulin profile, DPP4Is and/or SGLT2Is particularly (of course, glinide were not used, I think). If patients used these two agents in particular, it must affect the results (If patients did not use these two agents, authors should write detail of agents for T2DM in Table 1). Indeed, authors should investigate the association between MUAC and glycemic parameters because authors targeted T2DM patients. If authors are thinking there is no necessity to consider glycemic parameters in this study, this study's aim could not be understood by many of readers (including me) as they will not understand the difference between this study and the previous article. Moreover, authors must see the article, \[Hou Y, et al. BMJ Open 2019; 9: e028904. doi:10.1136/bmjopen-2019-028904\]. This article included 6287 participants with or without diabetes aged 40 years or older and was investigated from very various viewpoints. This article has already revealed almost all of this study's results except the participants for not only T2DM. Actually, I think this article did not have enough novelty, and this study cohort was not large. So what I wrote above must be investigated and mentioned in order to gain novelty; this study focused only T2DM patients.

In addition, medications of HT can also affect the results. Moreover, if patients were medicated by agents against hyperlipidemia and hyperuricemia, these must affect the results definitely. Authors should also investigate and mention them.

\<2\> Authors should explain log HOMAIR were used to investigation of association with MUAC. I would like to know why authors did not use HOMAIR itself. I would like to know whether authors considered statistical problem with using HOMAIR itself or not.

In summary, this article surely targeted T2DM patients, but more novelty were required. Statistical analysis itself was done properly, but considering novelty of this article or descriptions, it is insufficient, I think. Almost all of this article were very similar to the previous reports of non T2DM patients. Readers might think targeting only T2DM patients did not make sense at investigations like this. So, authors should reveal the impotence of this study properly. If authors could not confirm above all, this article is difficult to be accepted.

Regards,

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Submitted filename: Comments to Editor.docx

###### 

Click here for additional data file.
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Reviewer \#2: Dear authors,

This article is interesting because authors investigated the importance MUAC. However I think this article has unavoidable problems to be confirmed.

1、 Considering this study was performed for T2DM patients, authors should investigate the effect of T2DM itself to results in detail. Authors wrote "without insulin treatment or other medications that could alter insulin secretion (such as Sulphonylurea) for at least 2 weeks, not having severe disease and be free of any acute infection during 2 weeks before the inclusion" at MATERIALS and METHODS and patients' HbA1c levels in Table 1. At first, authors should write details of agents for T2DM which patients were administered when they were investigated. For instance, almost all agents for T2DM affected to insulin profile, DPP4Is and/or SGLT2Is particularly (of course, glinide were not used, I think). If patients used these two agents in particular, it must affect the results (If patients did not use these two agents, authors should write detail of agents for T2DM in Table 1).

Answer:

Thank you for your comment.

We've added the details of hypoglycemic agents in the MATERIALS AND METHODS and supplemental table 1 as you suggested. All the patients were treated without insulin treatment, Sulphonylurea, sodium-dependent glucose transporters-2 inhibitors (SGLT-2i) or glucagon-like peptide-1 (GLP-1) analog for at least 2 weeks. (see Paragraph 2 in Page 5 of the resubmitted manuscript with tracked changes)

2、Indeed, authors should investigate the association between MUAC and glycemic parameters because authors targeted T2DM patients. If authors are thinking there is no necessity to consider glycemic parameters in this study, this study's aim could not be understood by many of readers (including me) as they will not understand the difference between this study and the previous article. Moreover, authors must see the article, \[Hou Y, et al. BMJ Open 2019; 9: e028904. doi:10.1136/bmjopen-2019-028904\]. This article included 6287 participants with or without diabetes aged 40 years or older and was investigated from very various viewpoints. This article has already revealed almost all of this study's results except the participants for not only T2DM. Actually, I think this article did not have enough novelty, and this study cohort was not large. So what I wrote above must be investigated and mentioned in order to gain novelty; this study focused only T2DM patients.

Answer:

Thank you for your great comment.

We've added the analysis of the association between MUAC and glycemic parameters in the RESULTS, table 1, table 2 and table3 (see Paragraph 2 in Page 8 of the resubmitted manuscript with tracked changes). However, the association between MUAC and glycemic parameters was not observed in our research.

We acknowledged that Hou's study also focused on MUAC in the Chinese population. However, the study was different from ours. Firstly, the population in their study included both participates with diabetes or normal glucose tolerance (NGT). The analysis of association between MUAC and central obesity or IR was conducted in all the participants but not just in patients with diabetes. The only analysis specially involved with diabetes was the multivariable logistic regression analysis base on the subgroups of diabetes or not. The key points that two studies concerned were different. As the importance of IR in diabetes was reinforced in the most recent studies1-2 and the central obesity, IR and MUAC in diabetes were quite different from those in participants with NGTs3, the conclusion and significance of Hou's study could not be drawn to the population with diabetes. Secondly, the aim of Hou's study was to investigate the associations between MUAC and cardiometabolic risk profiles but not mainly the MUAC and central obesity and IR.

The relevant contents were added in the INTRODUCTION (see Paragraph 1 in Page 4 of the resubmitted manuscript with tracked changes) and DISCUSSION (see Paragraph 2 in Page 17 of the resubmitted manuscript with tracked changes).

We acknowledged that the sample size in our research was relatively small. However, this is just a pilot study evaluating the association between MUAC and central obesity and IR specially in patients with diabetes. With the suggestive findings from this study, prospectively designed studies with more participants would be conducted in the near future. The relevant contents were added in the DISCUSSION (see Paragraph 3 in Page 18 of the resubmitted manuscript with tracked changes).

\[1\] AHLQVIST E, STORM P, KARAJAMAKI A, et al. 2018. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables\[J\]. Lancet Diabetes Endocrinol, 6(5): 361-369.

\[2\] ZOU X, ZHOU X, ZHU Z, et al. 2019. Novel subgroups of patients with adult-onset diabetes in Chinese and US populations\[J\]. Lancet Diabetes Endocrinol, 7(1): 9-11.

\[3\] YANG Q, GRAHAM T E, MODY N, et al. 2005. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes\[J\]. Nature, 436(7049): 356-362.

3、In addition, medications of HT can also affect the results. Moreover, if patients were medicated by agents against hyperlipidemia and hyperuricemia, these must affect the results definitely. Authors should also investigate and mention them.

Answer:

Thank you for your comment.

We have added the details of the medications of hypertension, hyperlipidemia and hyperuricemia in the supplemental table 2, table3 and table4, respectively.

4、Authors should explain log HOMAIR were used to investigation of association with MUAC. I would like to know why authors did not use HOMAIR itself. I would like to know whether authors considered statistical problem with using HOMAIR itself or not.

Answer:

Thank you for your comment.

As we mentioned in the Statistical analysis (see Paragraph 1 in Page 7 of the resubmitted manuscript with tracked changes), data of non-normal distributions were logarithmically transformed before statistical analysis.

As a result, to ensure normality of distribution and to meet the criteria for regression analysis, we used log HOMAIR to investigate the association of HOMAIR and MUAC as many other studies did1-3.

\[1\] SANTHANAM P, ROWE S P, DIAS J P, et al. 2019. Relationship between DXA measured metrics of adiposity and glucose homeostasis; An analysis of the NHANES data\[J\]. PLoS One, 14(5): e0216900..

\[2\] MENTE A, MEYRE D, LANKTREE M B, et al. 2013. Causal relationship between adiponectin and metabolic traits: a Mendelian randomization study in a multiethnic population\[J\]. PLoS One, 8(6): e66808.

\[3\] ISHIMURA S, FURUHASHI M, WATANABE Y, et al. 2013. Circulating levels of fatty acid-binding protein family and metabolic phenotype in the general population\[J\]. PLoS One, 8(11): e81318.

Reviewer \#1:

1、This paper investigated the utility of measuring mid-upper arm circumference (MUAC) as a surrogate for measuring waist circumference or waist to hips ratio when assessing insulin resistance in patients with type 2 diabetes. It is concluded that MUAC is a simple tool to measure central obesity and insulin resistance. It is of interest that while MUAC correlated with BMI, waist circumference and and LDL-C in both genders, It failed to correlate with WHR, Tg, Uric acid, and HDL cholesterol in women. The implication of this failure in women was not discussed adequately. The possible reason (women are pear or apple shape while men are always apple shape) and possible consequence of using the MUAC as a clinical tool in women was not discussed.

Answer:

Thank you for your excellent comment.

It is interesting that while MUAC correlated with BMI, waist circumference and and LDL-C in both genders, but the correlation betwee MUAC and WHR, Tg, Uric acid, and HDL cholesterol in women was not observed. The plausible reason for this sex difference may be due to the different fat distribution during aging. Men have consistent fat distribution during aging, which is always characterized with more visceral fat in the abdomen (apple shape), but women have more subcutaneous fat in the hip and thighs(pear shape) before menopause and have more visceral fat in abdomen (apple shape) after menopause due to the dramatical decline of estrogen1. The female patients in our study, however, were mainly during the menopause period. As a result, no correlation was shown between MUAC and WHR in these estrogen-changing women. The differences of Tg, Uric acid, and HDL cholesterol also attributed to the decline of estrogen after menopause for the protective role of estrogen for metabolic diseases2. Therefore, using the MUAC as a clinical tool to detect some metabolic risk factors, such as WHR, Tg, Uric acid, and HDL cholesterol in women should be cautious.

The relevant contents were added in the DISCUSSION (see Paragraph 2 in Page 16 and Paragraph 1 in Page 17 of the resubmitted manuscript with tracked changes).

\[1\] KARASTERGIOU K, SMITH S R, GREENBERG A S, et al. 2012. Sex differences in human adipose tissues - the biology of pear shape\[J\]. Biol Sex Differ, 3(1): 13.

\[2\] TRAMUNT B, SMATI S, GRANDGEORGE N, et al. 2019. Sex differences in metabolic regulation and diabetes susceptibility\[J\]. Diabetologia.

2、On Page 19 Line 3 it is stated that \"Furthermore we found MUAC might be superior to WC in measuring IR in type 2 diabetes\...\" It would be helpful to the reader to quote here the data and statistical result that support this statement.

Answer:

Thank you for your comment.

We've added the data and statistical result on 16 Page Line 1.

3、Minor Points

Page 4 Para 2 Line 3 \"\...it remains a number of limitations od WC..\" should be \"\....there remain a number of limitations of WC..\"

Page 4 Para 2 Line 11 \"Therefore some Researches were conducted\.....\" should be \"Therefore som research was conducted\...\"

Page 4 Para 2 Line 15 \"However it remains little data to\...\" should be \"However there is little data to\...\"

There are many other examples where a native English speaker might help.

Answer:

We are sincerely sorry about the language issue. We have revised some mistakes as you suggested.

We'll seek help from English editing company and thoroughly review and revise the manuscript in the next revision.

###### 

Submitted filename: Supplemental file for review.docx

###### 

Click here for additional data file.
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Dear Dr Yao,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

We would appreciate receiving your revised manuscript by Feb 23 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Mauro Lombardo

Academic Editor

PLOS ONE

Additional Editor Comments (if provided):

Please answer to the 1st reviewer\'s comments and resubmit

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Partly

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: I Don\'t Know

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Thank you for addressing my concerns. Therefore it is now suitable for publication. I don\'t know if raw data has been made available.

Reviewer \#2: Dear authors,

I think authors reviewed and answered against my comment carefully. Meanwhile, there are some remaining important problems, especially in the data authors added.

I commented to authors about the novelty of this study considering the previous article with large numbers. Actually I understand there is the difference between this and the previous article with regard to the subjects (the subjects of this study were only patients of T2DM). However, partly because this study cohort were not large, I commented to authors about various points.

At first, authors should consider the effect to results by the administration of subjects more. The supplemental table which authors added showed the difficulty of proving correctness of authors' investigation and conclusion. I wrote that almost all agents for T2DM affected to HOMA-IR, especially not only sulphonylurea/glinide but also DPP4i /SGLT2i affected to insulin profile itself previously. Actually, authors could not remove the possibility of effect of anti-diabetic agents to the results and analysis of HOMA-IR. I even think it is possible diuretics or ARB/ACEi administration affected HOMA-IR.

Considering authors' opinion of the novelty of this study (the subjects of this study were only patients of T2DM), authors must remove the possibility of effect of anti-diabetic agents at least.

Same as above, authors should reconsider table 6 and related results. LDL-C must be affected by statin. 70 of 103 patients were with statin in this study. Authors must consider the effect of statin to the results and analysis.

Honestly, I think all subjects should be without anti-diabetic agents. Furthermore, if authors would like to mention about the relationships including LDL-C, the subjects should be without agents against hyperlipidemia or authors should investigate and analyze considering the effect of agents against hyperlipidemia.

I would like authors to understand my previous and present comments adequately.

Authors' revision considering these important points must be needed for this article to be accepted.

Regards,

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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20 Feb 2020

Point-by --Point Answers to

the Editor's and Reviewers' comments

Reviewer \#2: Dear authors,

I think authors reviewed and answered against my comment carefully. Meanwhile, there are some remaining important problems, especially in the data authors added.

I commented to authors about the novelty of this study considering the previous article with large numbers. Actually I understand there is the difference between this and the previous article with regard to the subjects (the subjects of this study were only patients of T2DM). However, partly because this study cohort were not large, I commented to authors about various points.

At first, authors should consider the effect to results by the administration of subjects more. The supplemental table which authors added showed the difficulty of proving correctness of authors' investigation and conclusion. I wrote that almost all agents for T2DM affected to HOMA-IR, especially not only sulphonylurea/glinide but also DPP4i /SGLT2i affected to insulin profile itself previously. Actually, authors could not remove the possibility of effect of anti-diabetic agents to the results and analysis of HOMA-IR. I even think it is possible diuretics or ARB/ACEi administration affected HOMA-IR.

Considering authors' opinion of the novelty of this study (the subjects of this study were only patients of T2DM), authors must remove the possibility of effect of anti-diabetic agents at least.

Same as above, authors should reconsider table 6 and related results. LDL-C must be affected by statin. 70 of 103 patients were with statin in this study. Authors must consider the effect of statin to the results and analysis.

Honestly, I think all subjects should be without anti-diabetic agents. Furthermore, if authors would like to mention about the relationships including LDL-C, the subjects should be without agents against hyperlipidemia or authors should investigate and analyze considering the effect of agents against hyperlipidemia.

I would like authors to understand my previous and present comments adequately.

Authors' revision considering these important points must be needed for this article to be accepted.

Regards,

Answer:

Thank you so much for your excellent comments.

First，honestly, we were very clear that all the pharmacotherapy of T2DM, hyperlipidemia or hypertention could definitely influenced insulin resistance. However, this was a cross-sectional study but not a case-control clinical trial, we could not intervene in any way to stop the anti-diabetic agents or any other medications as clinical trials do \[1-2\]. We can also see pharmacotherapy of patients with T2DM, hyperlipidemia or hypertention were not stopped in many similar studies involving the investigation of insulin resistance \[3-5\].

Second, we should admit that we could not completely eliminate all the influencing factors. For example, if we stopped the pharmacotherapy before evaluating HOMA-IR (note that the mean diabetes duration of patients in our study was 8\~9 years and the mean HbA1c was 9%), the plasma glucose would elevate, sometimes to a very high level. As is well known, the strongest insulin secretion influencing factor is glucose \[6\]. As a result, the elevating glucose would definitely influence the levels of insulin, and consequently influence HOMA-IR. Therefore, stopping the pharmacotherapy will still influence HOMA-IR.

Besides, in the guidelines of American Diabetes Association (ADA), European Association for the Study of Diabetes (EASD) or Chinese Diabetes Society (CDS), lifestyle intervention was recommended throughout the management of T2DM as a fundamental treatment \[7-8\]. The lifestyle management can also significantly change the insulin resistance \[9\]. However, subjects in studies with pharmacotherapy or not could not stop lifestyle management, which consequently could not avoid its effect on HOMA-IR.
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